An HLA-DP genetic test identifies inherited HLA-DPA1 and HLA-DPB1 alleles that combine to form HLA-DP class II molecules. These molecules present protein fragments to CD4 T cells and help coordinate immune responses. HLA-DP typing is used mainly in transplantation, especially when selecting an unrelated blood or marrow stem cell donor or defining donor-specific antibodies before solid-organ transplantation. A report is not simply normal or abnormal. Its meaning depends on how the patient’s alleles compare with a donor’s, whether a mismatch is predicted to be permissive or nonpermissive, and whether antibodies recognize the donor’s HLA-DP. HLA-DPB1 mismatches are common even among otherwise well-matched unrelated donor pairs because HLA-DP is inherited with more recombination than several neighboring HLA loci. Some mismatches can increase graft-versus-host disease, while others may be tolerated or even contribute to a graft-versus-leukemia effect. The transplant team interprets HLA-DP together with HLA-A, -B, -C, -DRB1, -DQB1, donor age, antibodies, disease urgency, and the planned graft-versus-host disease prevention strategy.
- HLA-DP testing reports tissue-type alleles rather than a normal range or disease score.
- HLA-DPB1 matching is often considered after core HLA-A, -B, -C, and -DRB1 compatibility is assessed.
- A mismatch may be classified as permissive or nonpermissive using T-cell epitope, expression, or related models.
- No fasting is needed; the sample is usually blood, saliva, or a cheek swab.
- HLA-DP antibodies can be donor-specific and clinically important, especially in kidney and other solid-organ transplantation.
- A matched HLA-DP result does not guarantee transplant success, and a mismatch does not automatically exclude a donor.
Table of Contents
- What HLA-DP Testing Measures
- When HLA-DP Typing Is Used
- How the Test Is Performed
- How to Read HLA-DP Results
- HLA-DPB1 Matching in Stem Cell Transplantation
- HLA-DP Antibodies in Solid-Organ Transplantation
- Disease Associations and Nontransplant Uses
- Limitations and Next Steps
What HLA-DP Testing Measures
HLA-DP is a class II HLA molecule made from two protein chains. HLA-DPA1 encodes the alpha chain, and HLA-DPB1 encodes the beta chain. Both genes lie in the major histocompatibility complex on chromosome 6. The alpha and beta chains pair on antigen-presenting cells and display peptides to CD4 T cells.
Each person usually inherits one HLA-DPA1 allele and one HLA-DPB1 allele from each biological parent. A high-resolution report may list results such as HLA-DPA101:03 and HLA-DPA102:01, plus HLA-DPB104:01 and HLA-DPB102:01. The paired alpha and beta chains form two or potentially more expressed HLA-DP heterodimers depending on how the chains combine.
Clinical transplant work focuses heavily on HLA-DPB1 because it is highly polymorphic and has well-developed mismatch models. HLA-DPA1 is increasingly relevant for complete antibody specificity and high-resolution compatibility, but many historical donor-selection algorithms were built around DPB1.
The result describes immune identity. There is no universally favorable HLA-DP type and no reference interval. Common alleles are not healthier than rare alleles. Interpretation comes from comparing two people or identifying whether an antibody recognizes a specific donor HLA-DP molecule.
HLA-DP differs from core linked loci because recombination between HLA-DPB1 and the rest of the HLA region occurs relatively often. As a result, a donor who matches a patient at HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 may still differ at HLA-DPB1. Roughly two-thirds or more of otherwise matched unrelated donor transplants have some DPB1 mismatch, depending on population and matching criteria.
A broad HLA typing test may include HLA-DP automatically, or it may be added after initial donor candidates are identified. The ordering team should specify whether it needs HLA-DPB1 only or both DPA1 and DPB1, and what resolution is required.
When HLA-DP Typing Is Used
HLA-DP testing is most often ordered for allogeneic hematopoietic cell transplantation. The patient and potential donors are typed to identify allele matches and to classify mismatches. The result may help rank two otherwise suitable donors.
Common uses include:
- selecting among 8/8 or 10/10 matched unrelated stem cell donors
- identifying a permissive rather than nonpermissive HLA-DPB1 mismatch
- confirming a donor’s HLA-DP alleles before collection
- evaluating donor-specific anti-HLA-DP antibodies
- assessing a virtual or physical crossmatch for kidney, heart, lung, liver, or pancreas transplantation
- investigating antibody-mediated rejection after transplant
- resolving an HLA typing ambiguity
- supporting research into immune disease, vaccine response, infection, or drug hypersensitivity
In stem cell transplantation, the importance of HLA-DP depends on graft-versus-host disease prophylaxis. Much of the classic evidence came from transplants using calcineurin-inhibitor and methotrexate-based approaches. Post-transplant cyclophosphamide can reduce the negative effect of some mismatches, so modern donor ranking is protocol specific.
In solid-organ transplantation, HLA-DP typing becomes important when the recipient has antibody reactivity that may target DP antigens. A donor-specific HLA-DP antibody can be missed if typing is incomplete or limited to the beta chain when the antibody recognizes an epitope influenced by the alpha chain.
HLA-DP disease associations are usually research or specialist tests rather than routine screening. Examples include associations with chronic beryllium disease, hepatitis B outcomes, autoimmune disorders, and certain drug reactions. A statistical association does not mean an allele causes disease, and most carriers remain unaffected.
Testing is not generally ordered to evaluate vague immune symptoms, recurrent infections, or “immune strength.” Those concerns require clinical evaluation and often different laboratory tests.
How the Test Is Performed
HLA-DP typing uses DNA from blood, saliva, or a cheek swab. Fasting is not needed. The laboratory amplifies HLA-DPA1 and HLA-DPB1 regions and assigns alleles by comparing the sequence with the international HLA database.
Methods include sequence-specific primers, sequence-specific oligonucleotide probes, Sanger sequencing, next-generation sequencing, and long-read sequencing. High-resolution next-generation sequencing is common in transplant laboratories because it can phase variants across longer regions and reduce ambiguous allele combinations.
Resolution matters. A low-resolution HLA-DPB104 result does not establish whether the allele is HLA-DPB104:01, *04:02, or another member of the group. These alleles may belong to different functional categories or carry different antibody epitopes. Donor selection generally uses at least two-field typing.
A standard workflow may include:
- preliminary donor typing or registry prediction
- high-resolution patient typing
- confirmatory donor typing from a new sample
- algorithmic classification of any HLA-DPB1 mismatch
- HLA antibody comparison and virtual crossmatch when relevant
- multidisciplinary donor selection
Turnaround varies from one or two days for urgent typing to several weeks for a broad donor search. Registry records may contain predicted or incomplete DPB1 types at first. Confirmatory testing must resolve the selected donor before transplantation.
The laboratory should know if the patient has undergone an allogeneic stem cell transplant. Blood DNA after transplant may represent the donor. A pre-transplant sample or another tissue may be needed to recover the recipient’s original type.
HLA typing is different from antibody testing. Typing identifies the inherited target molecules. Antibody testing asks whether the recipient’s serum reacts with HLA targets. A clinically meaningful evaluation often combines both with a crossmatch result.
Database updates can change an allele’s name or eliminate an ambiguity. The DNA is unchanged, but the report may look different. Laboratories should preserve the sequence evidence and database version so older and newer results can be reconciled.
How to Read HLA-DP Results
A high-resolution report may be organized by locus:
| Locus | Allele 1 | Allele 2 | What it encodes |
|---|---|---|---|
| HLA-DPA1 | HLA-DPA1*01:03 | HLA-DPA1*02:01 | HLA-DP alpha chains |
| HLA-DPB1 | HLA-DPB1*04:01 | HLA-DPB1*02:01 | HLA-DP beta chains |
The asterisk separates the gene from the allele name. The first field identifies an allele family, and the second usually distinguishes protein sequence. Third and fourth fields can indicate synonymous or noncoding differences. Suffixes may describe expression, such as a null allele.
A person can be homozygous, with the same allele on both chromosome copies, or heterozygous, with two different alleles. Neither state is inherently abnormal.
When comparing donor and recipient, the report may say:
- Matched: both tested alleles are the same at the chosen resolution.
- Single mismatch: one donor allele differs from the corresponding recipient allele.
- Double mismatch: both DPB1 alleles differ.
- Permissive mismatch: the predicted alloreactive difference falls into a category associated with lower excess risk under a particular model.
- Nonpermissive mismatch: the mismatch is predicted to provoke stronger clinically important alloreactivity.
- Graft-versus-host or host-versus-graft direction: describes which immune system can recognize the difference.
Permissive does not mean risk-free. It means the mismatch is predicted to be better tolerated than a nonpermissive alternative under the evidence used by the model. The full transplant regimen can modify that prediction.
A report may also include HLA-DP expression categories based partly on a regulatory variant linked to HLA-DPB1. Higher expression of a mismatched recipient HLA-DP can provide more target for donor T cells and has been associated with graft-versus-host disease. Expression models and T-cell epitope models evaluate different aspects of the same mismatch.
For antibody interpretation, the report may list possible HLA-DP heterodimers and epitopes. The alpha chain can influence the three-dimensional antibody target, so apparent DPB1 specificity sometimes needs DPA1 typing for confirmation.
HLA-DPB1 Matching in Stem Cell Transplantation
Unrelated donor selection usually begins with high-resolution matching at HLA-A, HLA-B, HLA-C, and HLA-DRB1. HLA-DQB1 and HLA-DPB1 add further refinement. When several donors are otherwise comparable, HLA-DPB1 can help identify the safer option.
The T-cell epitope, or TCE, model groups HLA-DPB1 alleles according to cross-reactive T-cell recognition. A donor–recipient mismatch within a compatible relationship is called permissive. A mismatch across less compatible groups is nonpermissive. Nonpermissive mismatches have been associated with more severe acute graft-versus-host disease and treatment-related mortality in conventional unrelated-donor transplantation.
Newer work refines the original TCE groupings by identifying a structural core of similar alleles and by measuring functional distance. These models attempt to explain why some allele differences stimulate strong alloresponses while others do not. Algorithms can classify a pair, but the laboratory and transplant team must verify the input alleles and model version.
HLA-DPB1 mismatch also has a potential graft-versus-leukemia effect. Donor T cells recognizing recipient HLA-DP can attack malignant blood cells, especially when the leukemia expresses class II HLA. This may reduce relapse while increasing graft-versus-host disease. Donor selection seeks a balance rather than complete immune silence.
The choice may differ for malignant and nonmalignant disease. In leukemia, some controlled alloreactivity may be beneficial. In aplastic anemia, inherited immune deficiency, or another nonmalignant condition, there is no tumor target, so avoiding damaging alloreactivity may receive more weight.
Post-transplant cyclophosphamide changes the picture. Recent large analyses suggest it can reduce the adverse effect of HLA-DPB1 mismatch compared with tacrolimus and methotrexate-based prophylaxis. In some PTCy settings, donor age, availability, and antibodies may be more important than obtaining a DPB1 match. Guidelines are evolving as these data mature.
The NMDP donor selection process considers DPB1 alongside core HLA matching, donor age, donor-specific antibodies, and clinical urgency. A younger donor with a permissive mismatch may be preferred over an older fully DPB1-matched donor, depending on the protocol. There is no universal ranking rule for every center.
Two donor candidates can therefore exchange rank when the transplant platform changes. Under a conventional calcineurin-inhibitor regimen, avoiding a nonpermissive DPB1 mismatch may carry substantial weight. Under a PTCy platform, the same mismatch may be more acceptable, particularly when the alternative donor is older, slower to collect, or targeted by a recipient antibody. This is why a laboratory result cannot be separated from the intended clinical protocol.
The recipient’s disease status also affects the tolerance for delay. A patient with aggressive leukemia may benefit more from a promptly available donor than from waiting weeks for a theoretically better DPB1 match. In contrast, a stable nonmalignant disorder may allow time for broader donor comparison. The team weighs transplant timing against incremental histocompatibility benefit.
Cord blood follows different matching rules because lower-resolution HLA matching and cell dose have major roles. HLA-DPB1 may be reported but is not interpreted with the same hierarchy used for a conventional adult unrelated donor. Haploidentical family transplantation also has distinct priorities, including donor-specific antibody avoidance and the chosen graft-versus-host disease prophylaxis.
HLA-DP Antibodies in Solid-Organ Transplantation
Recipients can develop HLA-DP antibodies after pregnancy, transfusion, or previous transplantation. These antibodies may exist before transplant or arise afterward. When an antibody recognizes the donor’s HLA-DP, it is a donor-specific antibody, or DSA.
HLA-DP DSAs can contribute to antibody-mediated rejection, transplant glomerulopathy, and graft loss, particularly in kidney transplantation. Risk depends on antibody strength, persistence, complement activity, crossmatch findings, and accompanying antibodies. Some isolated HLA-DP DSAs have little apparent effect, while others are clinically significant.
Single-antigen bead assays report fluorescence signals for recombinant HLA targets. Mean fluorescence intensity is semiquantitative and varies by laboratory. A high MFI is not automatically pathogenic, and a low MFI is not always harmless. Prozone effects, denatured antigens, shared epitopes, and assay background can distort the pattern.
Accurate donor typing is essential. An antibody may appear to target DPB1 but actually recognize a heterodimer epitope influenced by DPA1. Complete typing can prevent a false virtual crossmatch. A donor-specific antibody test should be reviewed by a histocompatibility specialist.
If a clinically important HLA-DP DSA is present, the center may avoid that donor, seek another donor, perform a physical crossmatch, or use a desensitization strategy. The decision depends on organ availability and the risk of remaining on the waiting list.
After transplant, rising HLA-DP DSA may prompt closer graft-function monitoring or biopsy. Treatment is based on the overall diagnosis of antibody-mediated rejection, not the antibody number alone.
Disease Associations and Nontransplant Uses
HLA-DP alleles affect peptide presentation and therefore appear in many association studies. One of the clearest clinical examples is chronic beryllium disease. HLA-DPB1 alleles carrying glutamic acid at position 69, often called Glu69, increase susceptibility in exposed workers. The allele does not cause disease without relevant exposure, and occupational evaluation also uses beryllium lymphocyte proliferation testing.
HLA-DP variants have been associated with hepatitis B persistence or clearance, vaccine antibody response, autoimmune disease, inflammatory conditions, and cancer outcomes. Most effect sizes are modest and population dependent. Linkage with nearby HLA genes can make it difficult to identify the causal locus.
Some drug-hypersensitivity studies report HLA-DP associations, but few have prescribing guidelines comparable with HLA-B57:01 for abacavir or HLA-B58:01 for allopurinol. A research association should not be used to avoid a medicine unless it has been clinically validated.
Consumer reports may describe an HLA-DP allele as “high risk” or “protective.” Such labels often ignore ancestry, exposure, competing genes, and absolute risk. Most HLA-DP alleles are common immune variants rather than pathogenic mutations. They are not classified as pathogenic, benign, or variants of uncertain significance in the same way as rare-disease genes.
HLA-DP typing may support population genetics, ancestry research, or paternity-related analysis, but clinical transplant laboratories do not use it as a general ancestry test. HLA frequencies overlap across populations and cannot define personal identity.
Limitations and Next Steps
HLA-DP interpretation is limited by assay resolution, phase ambiguity, database changes, and incomplete understanding of which molecular differences matter. A typing method that reads only selected exons may miss expression or noncoding variants. A two-field match may still contain differences at later fields, though not all such differences change protein function.
Mismatch models have defined uses. A TCE prediction validated in unrelated adult donor transplantation may not apply identically to cord blood, haploidentical donors, solid organs, pediatric disease, or every prophylaxis regimen. The algorithm should support—not replace—clinical judgment.
Common errors include:
- treating HLA-DP as a positive or negative health test
- assuming every mismatch carries the same risk
- interpreting “permissive” as completely safe
- ignoring donor-specific antibodies because DP was historically considered secondary
- comparing low-resolution and high-resolution reports as though they were equivalent
- using post-transplant blood to infer the recipient’s original HLA type
- relying on a consumer HLA imputation for donor selection
When results are incomplete, the next step may be repeat high-resolution typing, DPA1 addition, family segregation analysis, antibody dilution studies, or a physical crossmatch. If two donors remain similar, the transplant team can compare DPB1 permissiveness, age, availability, cytomegalovirus status, and other clinical factors.
The most useful question is not whether an HLA-DP result is “good.” It is whether a specific donor–recipient combination is acceptable for a specific transplant strategy, and whether any antibody recognizes the donor’s expressed HLA-DP molecules.
Questions about an HLA-DP mismatch
Ask whether the report refers to DPB1 allele matching, T-cell epitope permissiveness, expression level, donor-specific antibody, or an eplet model. These are different layers. A donor can be allele-mismatched yet TCE-permissive, or matched at one level while presenting an antibody target at another.
For stem cell transplantation using a calcineurin-inhibitor–based approach, a matched or permissively mismatched DPB1 donor may be preferred when other factors are similar. In post-transplant cyclophosphamide settings, current evidence may assign less priority to DPB1. The transplant center’s platform therefore changes the practical interpretation.
HLA-DPA1 can also contribute to the HLA-DP molecule and to antibody specificity. Many older reports focus on DPB1, so a complete antibody investigation may require DPA1 typing. High-resolution donor typing improves the virtual crossmatch when anti-DP antibodies are present.
A TCE category is not a personal danger score. It classifies predicted alloreactive groups and must be considered with HLA-A, -B, -C, and -DRB1 match, donor age, urgency, antibodies, and graft source. A younger available donor with a reasonable DPB1 relationship may be preferable to delaying transplant for a theoretical improvement.
If the laboratory reports only broad DP antigens, the transplant team may request allele-level DPB1 typing before applying a TCE algorithm. The algorithm requires an allele assignment that maps reliably to a T-cell epitope group. Ambiguous or novel alleles may need laboratory review rather than automated classification.
References
- New developments in the characterization of permissive HLA-DPB1 mismatches in hematopoietic cell transplantation 2024 (Review)
- Donor Selection for Allogeneic Hematopoietic Cell Transplantation 2023 (Review)
- Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Hematopoietic Cell Transplantation 2025 (Cohort Study)
- IPD-IMGT/HLA Database HLA-DPB1 T-Cell Epitope Algorithm 2025 (Official Resource)
- On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated complications 2022 (Review)
- Donor and cord blood unit selection guidelines 2025 (Guideline)
Disclaimer
This article is educational and does not replace interpretation by a transplant physician or accredited histocompatibility laboratory. HLA-DP results must be reviewed with the complete HLA match, donor-specific antibodies, crossmatch findings, disease type, donor factors, and graft-versus-host disease prevention plan. Do not accept or reject a donor from an isolated HLA-DP result.
